DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Bid/Ask 02:04:42 2024-06-12 pm EDT | ||
| 1.13 EUR | +0.89% |
|
| Current month | +17.89% | ||
| 1 month | +30.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 1.13 | +0.89% |
| 24-06-11 | 1.12 | -2.61% |
| 24-06-10 | 1.15 | +0.88% |
| 24-06-07 | 1.14 | +1.79% |
| 24-06-06 | 1.12 | +2.75% |
Real-time Boerse Frankfurt Warrants
Last update June 12, 2024 at 02:04 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM7327 |
| ISIN | DE000VM73278 |
| Date issued | 2024-01-05 |
| Strike | 130 $ |
| Maturity | 2025-06-20 (373 Days) |
| Parity | 10 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.15 € |
|---|---|
| Lowest since issue | 0.44 € |
| Spread | 0.01 € |
| Spread % | 0.88% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Certificates
- Certificat
